BC Platforms, a world leader in genomic data management and analytics, has closed a USD $15 million financing round alongside a new commercial collaboration with IQVIA™. The round was led by IQVIA in conjunction with Debiopharm Innovation Fund and Tesi, a Finnish venture capital and private equity company. As part of the collaboration, IQVIA and BC Platforms plan to launch new data driven technologies, integrating complex clinical and genomic data, to benefit transformational research.
BC Platforms, founded in 1997 from an MIT Whitehead project spinoff, is in the business of powerful genomic data management and analysis solutions. The company operates a Global Network of Biobanks known as BCRQUEST.COM, a streamlined solution for secure data sharing, analytics and governance, enabling greater collaboration for scientific innovation.
BC Platforms has global operations with its headquarters in Basel, Switzerland, research and development in Helsinki, Finland, and sales and marketing in London, Boston, and Vancouver. The company’s vision is to build the world’s leading analytics platform for healthcare and industry by 2020.
IQVIA is a leading global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. Formed in 2016 through the merger of IMS Health and Quintiles, IQVIA applies human data science, leveraging the analytic rigor and clarity of data science to the ever-expanding scope of human science, to enable companies to reimagine and develop new approaches to clinical development and commercialization, speed innovation and accelerate improvements in healthcare outcomes.
Powered by the IQVIA CORE™, IQVIA delivers unique and actionable insights at the intersection of large-scale analytics, transformative technology and extensive domain expertise, as well as execution capabilities. With approximately 65,000 employees, IQVIA conducts operations in more than 100 countries.
IQVIA and BC Platforms have a shared vision to build a world leading analytics platform to enable the pharmaceutical industry’s advancement of precision medicine, improving the efficiency of drug development and patient outcomes. BC Platforms technology will enhance IQVIA’s E360™ Genomics – a scalable, privacy-preserving genotypic-phenotypic database solution – in supporting a federated data network of genomic related analytics designed to protect patient privacy.
As part of its investment, IQVIA will have a designee on the BC Platforms’ Board of Directors. BC Platforms will use the fundraising proceeds to expand its global network of clinical and genomics data, delivering novel automated solutions to pharmaceutical companies. To date, the company has established partnerships with approximately 100 enterprise level healthcare systems and biobanks globally in 25 countries and has recently established an entity in Singapore to spearhead its growing activities in Asia.
“IQVIA and BC Platforms aim to combine genomic and clinical data assets around the world. IQVIA´s E360™ Genomics is built on patented techniques that allow us to build data access without compromising data privacy and security. Together with IQVIA´s deep healthcare expertise in managing and curating real-world data, we believe that we can accelerate precision medicine initiatives for patient benefits. This funding and commercial collaboration will help accelerate our growth in serving healthcare and Life Science customers as well as connecting data partners in a global, interoperable federated network.” – Tero Silvola, CEO at BC Platforms
“Drawing insights from integrated clinical-genomics data is a growing need of our life science and healthcare customers. Through the combination of BC Platforms technologies, which automates the workflow from genomic instruments to actionable insights, with IQVIAs leading real-world technologies platform we can enable customers to conduct novel research and discover new insights to advance healthcare.” – Rob Kotchie, President, Real World Solution, IQVIA
“We are dedicated supporters of innovation and believe that digital health and data accessibility are going to be key drivers of future healthcare research and development. We are delighted to be supporting BC Platforms, a leader in the field of genomic data management, in the next stage of their expansion and are excited by the potential of this collaboration with IQVIA.” – Tom Gibbs, Director at Debiopharm